Novo Nordisk Zenagamtide Phase 3 Obesity Trial Starts September 22, 2026: AMAZE 7 Head-to-Head Versus Semaglutide

Novo Nordisk (NVO) has a Phase 3 obesity trial reaching its expected start date of September 22, 2026, according to trial registration data tracked by BioSniper since September 2, 2026. The study — registered as AMAZE 7 — compares once-weekly subcutaneous zenagamtide directly against once-weekly subcutaneous semaglutide in participants with obesity. A head-to-head Phase 3 against semaglutide in obesity is one of the most consequential trial designs in the current cardiometabolic landscape, and it arrives with Novo Nordisk carrying a market capitalization of roughly $197.9 billion in our snapshot.

The event

The trial is registered in our catalyst dataset as:

"Efficacy and Safety of Zenagamtide s.c. Once-weekly Compared to Semaglutide s.c. Once-weekly in Participants With Obesity (AMAZE 7)"

The expected start date — September 22, 2026 — is recorded with "exact" date confidence. As of publication, no actual start is recorded in our data; the verified fact is the registered plan.

What's verified

• Company: Novo Nordisk A/S, ticker NVO, active listing status.
• Event type: Phase 3 trial start.
• Expected date: September 22, 2026, "exact" confidence.
• First tracked: September 2, 2026.
• Design elements from the registered title: zenagamtide subcutaneous once-weekly; comparator semaglutide subcutaneous once-weekly; population participants with obesity; endpoints named as efficacy and safety; study name AMAZE 7.
• Company scale: Market capitalization of $197,901,565,952 in our snapshot.
• Drug name provenance: Zenagamtide is parsed from the registered trial title (source: title_parse in our dataset).

What remains unknown

• Enrollment size: UNKNOWN in our data.
• Mechanism of action for zenagamtide: our record carries the name only, with no target or modality information — we will not describe it beyond the registered title.
• Primary endpoint formalities: "efficacy and safety" is the registered wording; structured endpoint fields are empty.
• Actual start and readout timing: not recorded.

Platform context: the AMAZE program and the obesity portfolio around it

AMAZE 7 is not an isolated study. Our tracker shows zenagamtide running through multiple parallel Phase 3 records:

• AMAZE 9 — "Efficacy and Safety of Once-daily Oral Zenagamtide in Participants With Obesity," expected September 1, 2026: an oral formulation of the same candidate, three weeks ahead of AMAZE 7's start.
• AMAZE 13 — "Efficacy and Safety of Zenagamtide s.c. Once-weekly in Asian Participants With Overweight or Obesity," expected January 7, 2027.
• A cardiometabolic-disease Phase 3 — zenagamtide once-weekly subcutaneous versus insulin glargine once-daily "in Participants With Type 2 Diabetes and Increased Cardiovascular" risk (title as registered), expected August 24, 2026.

An injectable-versus-injectable head-to-head (AMAZE 7), an oral Phase 3 (AMAZE 9), a regional expansion (AMAZE 13), and a diabetes-outcome study together sketch a candidate being positioned across the full obesity-diabetes continuum.

The same calendar shows how crowded Novo Nordisk's own obesity franchise is around zenagamtide:

• CagriSema (cagrilintide-semaglutide) — Phase 3 readouts recorded August 31, 2026 (REIMAGINE 1 in type 2 diabetes inadequately controlled on diet and exercise, and REIMAGINE 2 versus semaglutide or cagrilintide alone); a further Phase 3 readout recorded July 4, 2026 as an add-on to basal insulin; co-administration Phase 3 starts recorded June 30 and August 4, 2026; and multiple presentation-comparability and bioequivalence studies. Our outcome fields for these readouts are empty — results are not yet in our data.
• NNC0487-0111 — a Phase 3 versus semaglutide recorded May 20, 2026.
• Once-daily oral semaglutide — a Phase 3 in adults with overweight recorded August 12, 2026.

In total, our tracker holds 50 catalyst records for Novo Nordisk — one of only two companies in our current coverage whose calendar reaches that depth, alongside AbbVie.

Why a head-to-head against semaglutide matters

In our tracked dataset, semaglutide now appears in the comparator arm of at least two separate Novo Nordisk Phase 3 programs (zenagamtide in AMAZE 7, NNC0487-0111 recorded May 2026) while also being studied in oral form and combined as CagriSema. That is the registration-level fact; what it means competitively — a company stress-testing its own franchise against its next generation — is context our data can frame but not resolve. No efficacy data exists in our records for any of these studies.

How to track it

• Novo Nordisk company page — full catalyst calendar: https://biosniper.co/company/NVO
• This trial-start event page: https://biosniper.co/calendar/event/5796074

Bottom line

AMAZE 7 — zenagamtide once-weekly subcutaneous versus semaglutide once-weekly subcutaneous in obesity — reaches its registered Phase 3 start date of September 22, 2026, with exact date confidence. It is one of at least four zenagamtide Phase 3 records on our calendar spanning oral, regional, and diabetes-outcome designs, inside a 50-record Novo Nordisk calendar where CagriSema readouts and oral semaglutide sit in parallel lanes. Enrollment, mechanism, endpoints, and results are unknowns in our data — the design skeleton above is exactly what the registration states.